4.8 Article

Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus

Journal

NATURE COMMUNICATIONS
Volume 2, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms1453

Keywords

-

Funding

  1. Medical Research Council
  2. Parkinson's UK
  3. Brain Research Trust
  4. Alzheimer's Research UK
  5. Michael J. Fox Foundation
  6. Wellcome/MRC Parkinson's Disease Consortium
  7. University of Sheffield
  8. MRC Protein Phosphorylation Unit at the University of Dundee
  9. BBSRC [BBS/E/R/00001601, BBS/E/R/00001627] Funding Source: UKRI
  10. MRC [G1001253, G0800437, G0802760, MC_G1000735, G0802462, G108/638, G0701075] Funding Source: UKRI
  11. Alzheimers Research UK [ART-PPG2011A-14] Funding Source: researchfish
  12. Biotechnology and Biological Sciences Research Council [BBS/E/R/00001627, BBS/E/R/00001601] Funding Source: researchfish
  13. Medical Research Council [G1001253, MC_G1000735, G0800437, G0802760, G0700711B, G0701075, G108/638, G0802462] Funding Source: researchfish
  14. Parkinson's UK [K-0911, F-0902, G-0907, F-1002] Funding Source: researchfish

Ask authors/readers for more resources

A major barrier to research on Parkinson's disease is inaccessibility of diseased tissue for study. One solution is to derive induced pluripotent stem cells from patients and differentiate them into neurons affected by disease. Triplication of SNCA, encoding alpha-synuclein, causes a fully penetrant, aggressive form of Parkinson's disease with dementia. alpha-Synuclein dysfunction is the critical pathogenic event in Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Here we produce multiple induced pluripotent stem cell lines from an SNCA triplication patient and an unaffected first-degree relative. When these cells are differentiated into midbrain dopaminergic neurons, those from the patient produce double the amount of alpha-synuclein protein as neurons from the unaffected relative, precisely recapitulating the cause of Parkinson's disease in these individuals. This model represents a new experimental system to identify compounds that reduce levels of alpha-synuclein, and to investigate the mechanistic basis of neurodegeneration caused by alpha-synuclein dysfunction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available